Top Industry News

Novartis has announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing…

AbbVie has announced a new $380-million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. The facilities are the first in AbbVie’s…

Gilead Sciences has agreed to acquire Arcellx, a bio/pharmaceutical company focused on oncology, for $7.8 billion.   Kite, a subsidiary of Gilead Sciences, and Arcellx have an existing collaboration to co-develop and co-commercialize…

The latest from CDMOs, CMOs, and suppliers featuring Olon/Zymvol, Avid Bioservices and Univar Solutions.   Chemicals/Chemical API Manufacturing * Olon, Zymvol in Biocatalysis Pact Biologics Manufacturing * Avid Bioservices Opens New Early-Phase Center of Excellence Formulation Development/Drug Product Manufacturing * Univar Solutions Chosen as Ingredion Pharma…

Charles River Laboratories International, a CRO and CDMO, has agreed to sell certain of its European Discovery Services assets as well as its CDMO and Cell Solutions businesses in separate transactions.  In…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Viatris, GSK, Asahi Kasei, Novo Nordisk, and Boehringer Ingelheim. Highlights below.   For the latest news roundup on small and Emerging Pharma…

The latest from small and Emerging Pharma companies featuring Angelini Pharma, Generate:Biomedicines and Quiver Bioscience.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Angelini Pharma, Quiver Bioscience in…

Johnson & Johnson (J&J) has announced a more than $1-billion investment to build a new cell-therapy manufacturing facility in Montgomery County, Pennsylvania. The announcement is part of the company’s previously announced $55-billion investment in US-based manufacturing, research…

Monsanto, the crop-protection business of Bayer, has proposed a $7.25-billion US nationwide class settlement through a long-term claims program designed to resolve current and future claims over Roundup, a glyphosate-based herbicide, in which claimants allege Non-Hodgkin lymphoma injuries. The proposed…

The latest from CDMOs, CMOs, and suppliers featuring Recipharm, Axplora, Experic, MGS and DFE Pharma.   Chemicals/Chemical API Manufacturing * Scinai Acquires Recipharm IsraelFormulation Development/Drug Product Manufacturing * Axplora To Expand Lyophilization Capacity for ADCs* DFE Pharma Launches Continuous Manufacturing Platform * Recipharm Expanding High-Potency…